KIT and acute myeloid leukemia: We and others have reported that PP2A inhibition is a recurrent event in AML, and that restoration of PP2A phosphatase activity by treatment with PP2A-activating drugs (PADs) has antileukemic effects in both c-KIT wild-type (c-KIT−) and c-KIT mutated (c-KIT+) AML cells, inducing cell growth arrest and caspase-dependent apoptosis (12, 13, 29, 30, 33, 37).